Agile Therapeutics (NASDAQ:AGRX) Lifted to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Agile Therapeutics (NASDAQ:AGRXGet Rating) from a sell rating to a hold rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company’s lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey. “

A number of other equities analysts have also weighed in on AGRX. StockNews.com started coverage on shares of Agile Therapeutics in a research note on Wednesday, April 27th. They issued a sell rating for the company. Maxim Group lowered shares of Agile Therapeutics from a buy rating to a hold rating in a research note on Friday, April 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Agile Therapeutics presently has an average rating of Hold and an average price target of $135.30.

AGRX opened at $2.07 on Tuesday. Agile Therapeutics has a 12 month low of $1.82 and a 12 month high of $70.00. The company has a fifty day simple moving average of $10.82 and a 200 day simple moving average of $17.91. The stock has a market cap of $6.97 million, a P/E ratio of -0.07 and a beta of 1.57.

Agile Therapeutics (NASDAQ:AGRXGet Rating) last announced its earnings results on Wednesday, March 30th. The specialty pharmaceutical company reported ($8.00) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($6.80) by ($1.20). The company had revenue of $1.51 million during the quarter, compared to analyst estimates of $1.58 million. Agile Therapeutics had a negative return on equity of 376.29% and a negative net margin of 1,825.82%. During the same period in the previous year, the company posted ($8.00) earnings per share. On average, research analysts predict that Agile Therapeutics will post -15.8 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Agile Therapeutics by 2.5% during the 4th quarter. BlackRock Inc. now owns 1,507,654 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 37,394 shares during the last quarter. Summit Global Investments acquired a new stake in Agile Therapeutics in the 3rd quarter valued at about $121,000. Renaissance Technologies LLC lifted its stake in Agile Therapeutics by 341.6% in the 4th quarter. Renaissance Technologies LLC now owns 162,900 shares of the specialty pharmaceutical company’s stock valued at $80,000 after purchasing an additional 126,015 shares during the last quarter. GSA Capital Partners LLP lifted its stake in Agile Therapeutics by 25.1% in the 4th quarter. GSA Capital Partners LLP now owns 733,685 shares of the specialty pharmaceutical company’s stock valued at $358,000 after purchasing an additional 147,194 shares during the last quarter. Finally, First Citizens Bank & Trust Co. acquired a new stake in Agile Therapeutics in the 1st quarter valued at about $42,000. Institutional investors own 27.96% of the company’s stock.

About Agile Therapeutics (Get Rating)

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Further Reading

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.